We could not find any results for:
Make sure your spelling is correct or try broadening your search.
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.
RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial Plans in 2025 New Patent Filing Anticipated to...
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI...
LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath...
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical...
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.015 | 1.1811023622 | 1.27 | 1.33 | 1.1825 | 34818 | 1.28661157 | CS |
4 | 0.105 | 8.89830508475 | 1.18 | 1.55 | 1.1 | 92714 | 1.3149813 | CS |
12 | 0.235 | 22.380952381 | 1.05 | 1.58 | 0.7736 | 64963 | 1.23712787 | CS |
26 | 0.135 | 11.7391304348 | 1.15 | 1.58 | 0.7736 | 47861 | 1.19185329 | CS |
52 | -0.625 | -32.722513089 | 1.91 | 2.1199 | 0.7736 | 51675 | 1.28621953 | CS |
156 | -3.535 | -73.3402489627 | 4.82 | 5.745 | 0.5306 | 93940 | 2.33896177 | CS |
260 | -6.965 | -84.4242424242 | 8.25 | 16.74 | 0.5306 | 382748 | 7.56495923 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions